Beatriz Arrizabalaga

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti et al. · New England Journal of Medicine · 2020 · 519 citations · Full text

Independent Impact of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with Myelodysplastic Syndrome

Guillermo Sanz, Benet Nomdedeu, Esperanza Such et al. · Blood · 2008 · 115 citations

Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome in Infants

Gema Ariceta, Beatriz Arrizabalaga, Mireia Aguirre et al. · American Journal of Kidney Diseases · 2011 · 66 citations

Medicine, Hematology, Pediatrics +1

Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.

AF Remacha, Beatriz Arrizabalaga, Ana Villegas et al. · PubMed · 1999 · 63 citations

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti et al. · Blood · 2018 · 57 citations